• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于灵敏且特异测定血清中人前列腺腺激肽释放酶(hK2)的免疫荧光测定法。

Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum.

作者信息

Piironen T, Lövgren J, Karp M, Eerola R, Lundwall A, Dowell B, Lövgren T, Lilja H, Pettersson K

机构信息

Department of Biotechnology, University of Turku, Finland.

出版信息

Clin Chem. 1996 Jul;42(7):1034-41.

PMID:8674186
Abstract

Prostate-specific antigen (PSA) and human prostatic glandular kallikrein (hK2) have 79% identity with the primary structure. When we used recombinant hK2 protein, only 7 of 23 monoclonal anti-PSA IgGs (monoclonal antibodies, MAbs) cross-reacted with hK2, which enabled us to design a novel immunofluorometric MAb-MAb assay for the specific detection of hK2. In the first incubation, an excess of MAb 2H11, which does not cross-react with hK2, is added to prevent both free and complexed PSA from reacting in subsequent immunoreactions. In the second incubation, biotinylated MAb H50, which cross-reacts with hK2 by an epitope overlapping with MAb 2H11, served to bind only hK2 to the microtitration wells coated with streptavidin. In the third step, Eu-labeled MAb H117, which cross-reacts with hK2, detected the immobilized hK2. The hK2 assay was calibrated with recombinant hK2. The detection limit of the assay was 0.1 microgram/L, and the cross-reactivity with recombinant PSA was < or = 0.7%. The concentration of hK2 was measured in serum samples from 334 males with total PSA concentrations ranging from 1 to 3400 microgram/L. Most of the samples (57%) had hK2 concentrations below the detection limit. The proportions of hK2 relative to total PSA were 0-2% in 79%, 2-5% in 14%, 5-10% in 4%, and >10% in 3% of the samples. Gel filtration of 10 serum samples with increased hK2 concentrations showed a single peak of hK2 immunoreactivity with an apparent molecular size of approximately 30 kDa, corresponding to that of recombinant hK2 and free PSA.

摘要

前列腺特异性抗原(PSA)与人前列腺腺激肽释放酶(hK2)的一级结构有79%的同源性。当我们使用重组hK2蛋白时,23种单克隆抗PSA IgG(单克隆抗体,MAb)中只有7种与hK2发生交叉反应,这使我们能够设计一种新型免疫荧光MAb-MAb检测法来特异性检测hK2。在第一次温育中,加入过量的不与hK2交叉反应的单克隆抗体2H11,以防止游离和复合的PSA在随后的免疫反应中发生反应。在第二次温育中,生物素化的单克隆抗体H50通过与单克隆抗体2H11重叠的表位与hK2发生交叉反应,仅将hK2结合到包被有链霉亲和素的微量滴定孔中。在第三步中,与hK2发生交叉反应的铕标记单克隆抗体H117检测固定化的hK2。hK2检测法用重组hK2进行校准。该检测法的检测限为0.1微克/升,与重组PSA的交叉反应率≤0.7%。在334名总PSA浓度范围为1至3400微克/升的男性血清样本中测量hK2浓度。大多数样本(57%)的hK2浓度低于检测限。在79%的样本中,hK2相对于总PSA的比例为0-2%,14%的样本为2-5%,4%的样本为5-10%,3%的样本>10%。对10份hK2浓度升高的血清样本进行凝胶过滤,显示hK2免疫反应性的单峰,表观分子大小约为30 kDa,与重组hK2和游离PSA的分子大小一致。

相似文献

1
Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum.用于灵敏且特异测定血清中人前列腺腺激肽释放酶(hK2)的免疫荧光测定法。
Clin Chem. 1996 Jul;42(7):1034-41.
2
Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen.一种用于人腺体激肽释放酶的超灵敏免疫测定法的开发,该方法与前列腺特异性抗原无交叉反应。
Clin Chem. 1999 Jun;45(6 Pt 1):790-9.
3
Development of sensitive immunoassays for free and total human glandular kallikrein 2.游离和总人腺体激肽释放酶2的灵敏免疫测定法的开发。
Clin Chem. 2004 Sep;50(9):1607-17. doi: 10.1373/clinchem.2004.035253. Epub 2004 Jul 9.
4
Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.血清中人腺激肽释放酶2的灵敏且特异的免疫检测
Clin Chem. 2000 Feb;46(2):198-206.
5
The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.人腺体激肽释放酶的重要性及其在前列腺癌检测中与不同前列腺特异性抗原血清形式的相关性。
Cancer. 1998 Dec 15;83(12):2540-7.
6
Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2.用于检测游离人腺体激肽释放酶-2的高灵敏度自动化化学发光测定法。
Clin Chem. 1999 Jun;45(6 Pt 1):800-6.
7
Reactivity of anti-PSA monoclonal antibodies with recombinant human kallikrein-2.抗前列腺特异性抗原单克隆抗体与重组人激肽释放酶-2的反应性。
Tumour Biol. 1999;20 Suppl 1:35-7. doi: 10.1159/000056528.
8
Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity.人腺激肽释放酶(hK2)特异性单克隆抗体的研制:一种对前列腺特异性抗原交叉反应可忽略不计的hK2双抗体免疫测定法的研制
Urology. 1998 May;51(5):804-9. doi: 10.1016/s0090-4295(98)00107-1.
9
In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.在前列腺增生患者中,人腺体激肽释放酶与游离前列腺特异抗原的比值在总前列腺特异抗原4至10 ng/mL的诊断“灰色地带”内提高了前列腺癌与良性前列腺增生之间的鉴别能力。
Urology. 1998 Sep;52(3):360-5. doi: 10.1016/s0090-4295(98)00245-3.
10
Production of recombinant PSA and HK2 and analysis of their immunologic cross-reactivity.重组前列腺特异性抗原(PSA)和己糖激酶2(HK2)的制备及其免疫交叉反应性分析。
Biochem Biophys Res Commun. 1995 Aug 24;213(3):888-95. doi: 10.1006/bbrc.1995.2212.

引用本文的文献

1
A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer.一项评估放射性标记的靶向人 Kallikrein 2 抗体在转移性去势抵抗性前列腺癌患者中的生物分布和药代动力学的 0 期研究。
J Nucl Med. 2024 Jul 1;65(7):1051-1056. doi: 10.2967/jnumed.124.267416.
2
Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort.前瞻性验证 microseminoprotein-β 联合 4Kscore 预测国际多中心队列中高级别前列腺癌的价值。
BJU Int. 2021 Aug;128(2):218-224. doi: 10.1111/bju.15320. Epub 2020 Dec 28.
3
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy.
优化 hK2 靶向α粒子治疗抵抗的前列腺癌小鼠模型的遗传特征。
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15172-15181. doi: 10.1073/pnas.1918744117. Epub 2020 Jun 12.
4
A predictive model for prostate cancer incorporating PSA molecular forms and age.包含 PSA 分子形式和年龄的前列腺癌预测模型。
Sci Rep. 2020 Feb 12;10(1):2463. doi: 10.1038/s41598-020-58836-4.
5
Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men.在极高危男性中,前列腺癌根治术前血液中激肽释放酶标志物的表现可预测术后早期复发和转移。
Prostate. 2020 Jan;80(1):51-56. doi: 10.1002/pros.23916. Epub 2019 Oct 11.
6
A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.四激肽酶 panel 和 β-微 Seminoprotein 在前列腺穿刺活检预测高级别前列腺癌中的应用:芬兰参与的欧洲前列腺癌筛查随机研究的独立验证。
Eur Urol Focus. 2019 Jul;5(4):561-567. doi: 10.1016/j.euf.2017.11.002. Epub 2017 Nov 11.
7
Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC).欧洲癌症与营养前瞻性调查(EPIC)中的输精管切除术与前列腺癌风险
J Clin Oncol. 2017 Apr 20;35(12):1297-1303. doi: 10.1200/JCO.2016.70.0062. Epub 2017 Mar 6.
8
A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.四激肽释放酶检测组合可预测活检时的高级别癌症:在社区队列中的独立验证
Eur Urol. 2016 Mar;69(3):505-11. doi: 10.1016/j.eururo.2015.04.028. Epub 2015 May 13.
9
Biomarkers in prostate cancer surveillance and screening: past, present, and future.前列腺癌监测和筛查中的生物标志物:过去、现在和未来。
Ther Adv Urol. 2013 Dec;5(6):318-29. doi: 10.1177/1756287213495915.
10
Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men.KLK2 和 KLK3 中的遗传变异与年轻男性血清和精液中 hK2 和 PSA 的浓度相关。
Clin Chem. 2014 Mar;60(3):490-9. doi: 10.1373/clinchem.2013.211219. Epub 2013 Nov 22.